PDTC enables type I TRAIL signaling in type II follicular lymphoma cells

Nuutinen, Ulla; Simelius, Niina; Ropponen, Antti; Eeva, Jonna; Mättö, Mikko; Eray, Mine; Pellinen, Riikka; Wahlfors, Jarmo; Pelkonen, Jukka

doi:10.1016/j.leukres.2008.09.025

« Previous Next »Leukemia Research
Volume 33, Issue 6 , Pages 829-836, June 2009

PDTC enables type I TRAIL signaling in type II follicular lymphoma cells

Ulla Nuutinen
- Department of Clinical Microbiology, Institute of Clinical Medicine, University of Kuopio, Yliopistonranta 1C, 70210 Kuopio, Finland
- Corresponding author. Tel.: +358 50 5361299; fax: +358 17 162705.
Niina Simelius
- Department of Clinical Microbiology, Institute of Clinical Medicine, University of Kuopio, Yliopistonranta 1C, 70210 Kuopio, Finland
Antti Ropponen
- Department of Clinical Microbiology, Institute of Clinical Medicine, University of Kuopio, Yliopistonranta 1C, 70210 Kuopio, Finland
Jonna Eeva
- Department of Clinical Microbiology, Institute of Clinical Medicine, University of Kuopio, Yliopistonranta 1C, 70210 Kuopio, Finland
Mikko Mättö
- Department of Clinical Microbiology, Institute of Clinical Medicine, University of Kuopio, Yliopistonranta 1C, 70210 Kuopio, Finland
Mine Eray
- Department of Pathology, Haartman Institute, University of Helsinki, Haartmaninkatu 3, 00014 Helsinki, Finland
Riikka Pellinen
- Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Kuopio, Neulaniementie 2, 70210 Kuopio, Finland
Jarmo Wahlfors
- Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Kuopio, Neulaniementie 2, 70210 Kuopio, Finland
Jukka Pelkonen
- Department of Clinical Microbiology, Institute of Clinical Medicine, University of Kuopio, Yliopistonranta 1C, 70210 Kuopio, Finland
- Department of Clinical Microbiology, Kuopio University Hospital, Puijonlaaksontie 2, 70210 Kuopio, Finland

Received 13 August 2008; received in revised form 24 September 2008; accepted 25 September 2008. published online 07 March 2011.

Abstract

Based on Bcl-X_L overexpression studies we identified type I and type II follicular lymphoma cell lines in response to TRAIL. We demonstrate here that either amount of caspase-8 activation or Bid cleavage could not define the dependence on mitochondria. Furthermore, an inhibitor of NF-κB, PDTC, enabled TRAIL to activate type I apoptotic pathway in type II cells. However, an inhibitor of IKK did not switch apoptosis to type I pathway in type II cells, indicating that NF-κB might not be responsible for the switch.

Keywords: TRAIL, Mitochondria, Apoptosis, Human, Follicular lymphoma, Bcl-X_L, Caspase-9, NF-κB